DYN
NASDAQDyne Therapeutics Inc.
Price$17.67-0.90 (-4.85%)
01:30 PM07:45 PM
News · 26 weeks108-71%
2025-12-142026-06-07
Mix8190d
- SEC Filings43(53%)
- Insider26(32%)
- Other12(15%)
Latest news
25 items- INSIDERSEC Form 4 filed by Director Hurwitz Edward4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 4 filed by Director Lubner David Charles4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 4 filed by Director Rhodes Jason P4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 4 filed by Director Kersten Dirk4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 4 filed by Director Incerti Carlo4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERSEC Form 4 filed by Director Stehman-Breen Catherine4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERDirector Posner Brian S bought $33,880 worth of shares (2,000 units at $16.94), increasing direct ownership by 9% to 24,500 units (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECDyne Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
- INSIDERDirector Posner Brian S bought $43,700 worth of shares (2,500 units at $17.48), increasing direct ownership by 12% to 22,500 units (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECDyne Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
- PRDyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the completion of enrollment in the registrational expansion cohort (REC) of the Phase 1/2 ACHIEVE trial of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in individuals with DM1. "Completing enrollment in the registrational expansion cohort of ACHIEVE is a critical milestone as we advance a potentially best-in-class therapy designed to a
- INSIDERDirector Posner Brian S bought $36,420 worth of shares (2,000 units at $18.21), increasing direct ownership by 11% to 20,000 units (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- PRDyne Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)- Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion cohort of the DELIVER trial, treatment with z-rostudirsen resulted in a robust and statistically significant increase in dystrophin production with functional improvement observed across multiple clinical endpoints and a favorable safety profile1 - - Proposed dosing regimen of 20 mg/kg administered intravenously once every 4 weeks (Q4W) - WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announc
- INSIDERDirector Posner Brian S bought $42,800 worth of shares (2,500 units at $17.12), increasing direct ownership by 16% to 18,000 units (SEC Form 4)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- PRDyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 17 newly hired employees. The awards were made as an inducement material to the newly hired employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 296,500 shares of Dyne's common stock at a per share exercise price equal to the closing price of Dyne's common stock
- PRDyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle and pulmonary function - - FORZETTO trial design and protocol aligned with FDA; trial intended to serve as confirmatory trial for traditional approval in the U.S. and support ex-U.S. marketing applications - WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the initiation of the Phase 3 FORZETTO trial of
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dyne Therapeutics Inc.SCHEDULE 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
- INSIDERChief Commercial Officer Friedl-Naderer Johanna sold $4,186 worth of shares (228 units at $18.36) as part of a pre-agreed trading plan, decreasing direct ownership by 0.15% to 154,353 units (SEC Form 4) to cover withholding tax4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERChief Medical Officer Kerr Douglas sold $28,715 worth of shares (1,564 units at $18.36) as part of a pre-agreed trading plan, decreasing direct ownership by 0.91% to 170,042 units (SEC Form 4) to satisfy withholding obligation4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERChief Financial Officer Lucera Erick sold $26,585 worth of shares (1,448 units at $18.36) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 123,925 units (SEC Form 4) to cover taxes4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- INSIDERCEO & President Cox John sold $60,790 worth of shares (3,311 units at $18.36) as part of a pre-agreed trading plan, decreasing direct ownership by 0.88% to 370,834 units (SEC Form 4) (withholding obligation)4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- SECSEC Form 144 filed by Dyne Therapeutics Inc.144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
- PRDyne Therapeutics to Participate in Upcoming Investor ConferencesWALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: 2026 RBC Capital Markets Global Healthcare Conference, fireside chat on Wednesday, May 20, 2026 at 11:00 a.m. ET in New York, NY2026 Jefferies Global Healthcare Conference, fireside chat on Wednesday, June 3, 2026 at 9:55 a.m. ET in New York, NYGoldman Sachs 47th Annual Global Healthcare Conference 2026, hosting meetings on Tuesday, June 9, 2026 in Miami, FL A li
- SECDyne Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
DYN FAQ
7 questionsWhat does Dyne Therapeutics Inc. do?
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.Where does DYN stock trade?
Dyne Therapeutics Inc. (DYN) is listed on NASDAQ.What sector and industry is DYN in?
Dyne Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dyne Therapeutics Inc. go public?
Dyne Therapeutics Inc. (DYN) completed its IPO in 2020.What are analysts saying about DYN?
Dyne Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform with a $4000.00 price target on 2025-12-10. Recent price targets range from $1300.00 to $4600.00.What companies are similar to DYN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DYN side-by-side with any of them on Quantisnow.How can I track DYN on Quantisnow?
Quantisnow aggregates Dyne Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DYN to receive live email and push alerts on every new disclosure.